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Primary screening for cervical cancer precursors has considerably evolved with the introduction of new technology to
improve the early detection of disease. The objective of this study was to elaborate a diagnostic pathway integrating liquid-
based and computer-assisted cytology and human papillomavirus DNA testing to focus screening on women at risk which
may be more cost-effective for the healthcare system. A single laboratory analysis was conducted during a 5-month period
using liquid-based cytology followed by human papillomavirus DNA testing for women with an abnormal result or with
previous abnormal cytology. Human papillomavirus prevalence was estimated by testing 909 consecutive unselected samples.
All slides were then rescreened using automated cytologic testing and triaged into a high- or low-score group according to
computer results. Of the 8676 slides scanned, 352 had a test result of atypical squamous cells of undetermined signiﬁcance
or worse. Two hundred and ninety-seven (84.3%) samples with an atypical squamous cells of undetermined signiﬁcance or
worse result and 100% of those with detection of high-grade squamous intraepithelial lesions and carcinomas (HSIL+) were
triaged into the high-score group. The combination of instrument scores and human papillomavirus results indicated that
51.0% of high score/human papillomavirus-positive cases should be considered as ASCUS+, while 99.6% of low-score/human
papillomavirus negative cases remained negative in the ﬁnal cytologic diagnosis, representing 49.0% of all cases. Of the
screened women 89.5% should test negative for human papillomavirus and be reported as such in the ﬁnal cytologic
diagnosis. In conclusion, preliminary results suggest that this diagnostic pathway has the potential to improve primary cervical
cancer screening and cost-effectiveness. By using a combination of testing methods to focus screening and clinical attention
to cases at risk, it would be possible to lengthen screening intervals for 90% of women and to archive without further
review all low-score/human papillomavirus-negative slides, representing 50% of the screening workload.
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Concern about the reliability of cervicovaginal cytology as a screen-
ing technique has been repeatedly voiced by both the public and
health professionals in Europe and the United States. New technol-
ogies such as liquid-based cytology, automated computer-assisted
screening, and human papillomavirus (HPV) DNA testing have
enabled signiﬁcant progress to be made in this important area of
women’s health.
Liquid-based, thin-layer cytology reduces sampling and prepara-
tion errors of the conventional smear. It has demonstrated
improved specimen adequacy and sensitivity for the detection of
cervical cancer and its cytologic precursors, squamous intraepithe-
lial lesions (SILs) (Vassilakos et al, 2000), while providing less
equivocal results and has led to 10% fewer recalls for repeat testing
(Vassilakos, 1998a). Screening time of a thin-layer slide is also
considerably shorter compared with the conventional smear (Vassi-
lakos, 1998).
The AutoCyte PREP system (Tripath Imaging Inc, Burlington,
NC, USA) is an automated screening tool for thin-layer processing.
Independent studies have shown it to be signiﬁcantly more effec-
tive for the detection of both low-grade squamous intraepithelial
lesions (LSILs) and more severe diagnoses (Marino and Fremont-
Smith, 2001; Vassilakos et al, 2000).
To further reduce screening or interpretation errors, automated
devices were introduced as primary screeners or quality control
instruments. The AutoPap system (Tripath Imaging inc, Burling-
ton, NC, USA) addresses both sources of error. It has shown
both superior sensitivity and speciﬁcity in the identiﬁcation of all
cervical abnormalities including atypical squamous cells of undeter-
mined signﬁcance (ASCUS) and LSILs alone or higher, when
compared to current laboratory practice (Wilbur et al, 1998). A
recent study found that the AutoPap system demonstrates the same
capacities to detect and score abnormal liquid-based thin-layer
slides as it does for abnormal conventional smears (Vassilakos et
al, 2001).
Detection of high-risk HPV (HR-HPV) types by the Hybrid
Capture II system (Digene Corporation, Gaithersburg, MD,
USA) is of diagnostic and prognostic value. Recent studies show
that HR-HPV types are strongly associated with SIL severity
and cervical cancer (Bosch et al, 1995; Nobbenhuis et al,
1999; Walboomers et al, 1999). Persistence of these types is a
necessary factor for the development of SIL and the subsequent
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The majority of SILs without a HR-HPV type regress and minor
cervical abnormalities such as ASCUS or LSIL in a HPV-negative
patient are more likely to be false-positive cytologic diagnoses
(Sherman et al, 1994; Cox et al, 1995). In addition, recent data
indicate that HPV testing may be used efﬁciently in the manage-
ment of ASCUS cases by referring to colposcopy only those
women who test positive (Vassilakos et al, 1998; Solomon et al,
2001). Used as an adjunct to conventional or liquid-based cytology,
HPV DNA testing has the potential to increase the sensitivity and
speciﬁcity of primary screening (Cox et al, 1995; Ferenczy et al,
1996; Vassilakos et al, 1998). The high negative predictive value
of the combined test, close to 100%, may improve cost-effective-
ness by permitting screening intervals to be lengthened (Cuzick
et al, 1999).
It can be postulated that a combined use of these three technol-
ogies could help to obtain improved levels of prognostic
information and accuracy. The objective of our pilot study was
to design a diagnostic pathway for a new screening option and
patient management protocol so as to better focus attention to
women who are at risk of having signiﬁcant cervical abnormalities.
MATERIALS AND METHODS
Cohort study participants were 8676 women who had a routine
cervical Pap examination in Geneva, Switzerland, between Septem-
ber 2000 and January 2001, a population already studied with a
low incidence of cervical cancer (Vassilakos et al, 2002). No selec-
tion criteria were applied to the cohort. Liquid-based samples were
obtained from 33 gynaecologists of the region for routine screening
purposes. A subset of 10% of specimens was created to determine
the prevalence of HPV infection in the study population. Table 1
shows the age distribution in both the cohort and subset. No other
socio-demographic data were collected. The study design is
summarized in Figure 1. Women were informed of the purpose
of the study by their gynaecologist and gave their consent to use
residual material from their samples.
AutocytePrep cytology and interpretation
Within 48 h of collection, a thin-layer cervicovaginal slide was
prepared using the robotic AutoCyte PREP system according to
the manufacturer’s instructions. In brief, the method uses a
24% ethanol-based preservative and the processing steps include
vortexing, density gradient enrichment by centrifugation, decant-
ing and resuspension of cell pellets followed by gravity
sedimentation onto a cationically-coated slide, and automated
Papanicolaou staining. All slides were initially processed according
to the routine screening procedure of the Institute of Pathology,
Geneva (Figure 1, step I).
Suspicious cases and those with a history of previous abnormal
cytology were reviewed by a senior cytotechnician and forwarded
to the cytopathologist (P Vassilakos) for ﬁnal diagnosis. Final case
diagnoses were classiﬁed according to the Bethesda nomenclature
system and were considered as ‘reference diagnoses’.
HPV DNA testing
Following preparation of the AutocytePrep slides, the remaining
samples were used, according to our usual procedure, to conduct
HPV DNA detection in patients reported positive for ASCUS or
atypical glandular cells of undetermined signiﬁcance (AGUS), or
worse. Patients with normal results but with a previous history
of abnormal cytology were also tested. The prevalence of HPV
infection in the study population was estimated by testing a subset
of 10% of unselected consecutive cases.
HPV testing was performed on a routine basis using the Hybrid
Capture II assay. Each centrifuge tube contained 0.8 ml of residual
cervical cells in water and was centrifuged at 800+15 g for
10+1 min. The supernatant was decanted and the residual
removed by blotting the inverted tube on clean absorbent paper.
Specimen Transport Medium (STM, Digene) (200 ml) was added
to each cervical cell pellet and the tube vortexed for 15 s to resus-
pend the pellet. Denaturation reagent of 100 ml was then added to
produce single-stranded DNA reacting with 13 full-length RNA
probes recognizing HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68, vortexed for 5 s, and incubated in a
65+28C water bath for 90+5 min. The denatured specimen was
then immediately tested by using the Hybrid Capture II assay
according to manufacturer’s instructions. A test was considered
positive for the presence of HR-HPV-DNA if the relative light unit
(RLU) obtained from the luminometer equalled to or exceeded the
mean of the three positive control values (cut-off value equal to
1.0 pg ml
71). A RLU measurement 51.0 pg ml
71 indicated either
the absence of the 13 HR-HPV types or HPV DNA levels below the
threshold of detection.
AutoPap classiﬁcation scores
AutocytePrep slides were then subjected to the AutoPap, an
automated primary screener (Figure 1, step II). A report was
generated and each slide, based on the device assessment, was
triaged into the following categories: ‘no further review’ (NFR),
‘review’ (R), ‘process review’ (PR), or ‘rerun’. A slide designated
as NFR has a low probability of abnormality, and an R slide has
a higher likelihood according to its ranking on a scale of 1 to 5,
an aggregate measurement of numerous cytologic parameters.
The higher the assigned score, the more likely a smear contains
abnormalities and the lower the assigned score, the more likely a
smear is negative. Each slide was also assigned an individual rank
score expressed as a fraction and as a percentage. A high-score
group was deﬁned by including the 1st, 2nd and 3rd rank,
and a low-score group by including the 4th, 5th and NFR cate-
gory.
Data analyses
All the results were entered into a Microsoft Access database
(Redmond, Washington, USA) for analysis and elaboration of the
screening and management diagnostic pathway (Figure 1). Trends
were assessed with the chi-square test.
RESULTS
From September 2000 to January 2001, a total of 9665 specimens
were collected and initial screening was conducted using the
AutoPap system. Of these, 8688 (89.9%) qualiﬁed for scanning
and 977 (10.1%) were classiﬁed as PR and were excluded from
the study because rerun was impossible. Nine hundred and sixty-
ﬁve were cytologically negative and 12 were positive (one HSIL,
ﬁve LSIL and six ASCUS). HPV DNA testing could not be
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Table 1 Age distribution in the study population and subset
a
Age (years) Study population (n=8676) (%) Subset
a (n=909) (%)
425 875 (10.1) 83 (9.2)
26–35 2124 (24.5) 214 (23.7)
36–45 2176 (25.1) 233 (25.7)
46–55 1768 (20.4) 183 (20.2)
56–65 1118 (12.9) 113 (12.6)
465 615 (7.1) 83 (9.2)
aSubset comprising of unselected consecutive cases from the study population to
determine the prevalence of HR-HPV types.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 382–388performed for 12 positive cases (one AGUS, nine LSIL, two HSIL)
because the residual sample was considered to be unsatisfactory or
the clinician did not propose an HPV test. Finally, 8676 cases were
included in the study.
The age-group distribution of the subset of 909 cases to estimate
the prevalence of HPV was similar to the entire study population
(Table 1). A prevalence of 9.5% (87 out of 909) for HR-HPV types
was found. Following a further breakdown of HPV positives into
high-score and low-score groups, the prevalence for each group
was 9.8% (44 out of 447) and 9.3% (43 out of 462), respectively.
We assumed that the prevalence for the total population screened
should be distributed similarly. Table 2 presents the correlation
between AutoPap slide classiﬁcation results and cytologic diagnosis.
Figure 2 summarizes results according to the combination of
AutoPap scores, HPV testing, and ﬁnal cytologic diagnoses. Of
the 8676 slides scanned, 4009 (46.0%) were assigned to the high-
score group and 4667 (54.0%) to the low-score group. The distri-
bution according to the combined results is represented as follows:
51.0% of high-score/HPV-positive cases were diagnosed as
ASCUS+, while 8% of low-score/HPV-positive cases were diag-
nosed as ASCUS+. High-score and low-score/HPV-negative cases
were negative at manual screening in 97.3 and 99.6%, respectively.
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Unselected consecutive liquid-
based samples (CytoRich vial)
AutoCyte PREP thin-layer slides
Cytotechnicians
Routine screening practice
Final cytologic diagnosis
• Negative results with past
history of abnormal cytology
• ASCUS; LSIL; HSIL; Cancer
• 10% of cases*
HPV-DNA detection from the
remaining CytoRich sample
by Hybrid Capture II
DATABASE
Results
Diagnostic
pathway
AutoPAP primary screener
Report with slide designation
• Review
(with rank)
• No further
review
Process
review or
rerun
Able to
rerun
slides?
Exclusion
from the
study
no yes
II I
Figure 1 Study design. ASCUS=atypical squamous cells of undetermined signiﬁcance; LSIL=low-grade squamous intraepithelial lesion; HSIL=high-grade
squamous intraepithelial lesion; Cancer=squamous cell or other invasive carcinoma. *Subset composed by unselected consecutive cases from the cohort
study population to determine HR-HPV types prevalence.
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British Journal of Cancer (2002) 86(3), 382–388 ã 2002 The Cancer Research CampaignAn association was found between HPV positivity and cyto-
logic diagnosis. Sixty-six out of 868 (7.6%) of cytologically-
negative cases without a past history of abnormal cytology were
HPV-positive. In contrast, 21.7% (63 out of 290) of cytologi-
cally-negative cases with a past history of abnormal cytology
were HPV-positive. Finally, 35.9% (46 out of 128) of ASCUS,
83.7% (150 out of 179) of LSIL and 95.5% (43 out of 45)
of HSIL+ were HPV-positive. Chi-square for trend were 575,
P50.001.
HR-HPV positivity and automated scoring were not closely
related. This is not surprising since the Autopap system uses a
statistical classiﬁer algorithm to assign a numerical score to each
slide. In the presence of benign cellular changes sharing some
morphologic similarities with signiﬁcant cervical abnormalities,
the slide is triaged into the high-score group. These slides may
be HR-HPV negative. On the other hand, HPV positivity is found
in samples without cervical abnormalities; in these cases, the slide
may be triaged into the low-score group.
DISCUSSION
Although organized screening programs based on the Papanicolaou
(Pap) smear have been very successful in reducing mortality, a
major problem has emerged. Cervical cancer has not been eradi-
cated and its incidence has remained virtually constant for
several years. In Switzerland, cervical cancer is still among the 10
leading causes of cancer with approximately 400 new cases and
100 deaths annually, mostly occurring in women over 65-years-
old (Ligue Suisse Contre le Cancer, 1998). The majority of cases
have never had a Pap test, or have not had one in the previous
5 years.
However, false-negative results from Pap smears do occur, lead-
ing to deaths in routinely screened women. Results of one study
showed that 14% of women with an invasive cervical cancer or
HSIL had received a negative smear result within the 2 years prior
to diagnosis. Approximately two-thirds of false-negative smears
were related to sampling errors, and the remaining third were
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AutoPap thin-layer
slide classification
(n=8676)
High-score
(n=4009)
HPV–
(n=3616)
HPV+
(n=393)
Cytology
positive
(n=200)
Cytology
negative
(n=193)
Cytology
positive
(n=97)
Cytology
negative
(n=3519)
ASCUS: 74
LSIL: 21
HSIL: 2
ASCUS: 39
LSIL: 118
HSIL: 41
Cancer: 2
Low-score
(n=4667)
HPV–
(n=4231)
HPV+
(n=436)
Cytology
positive
(n=39)
Cytology
negative
(n=397)
ASCUS: 7
LSIL: 32
Cytology
positive
(n=16)
Cytology
negative
(n=4215)
ASCUS: 8
LSIL: 8
46.0% 54.0%
90.2% 9.8%
51.0% 49.0% 2.7% 97.3%
9.3% 90.7%
0.4% 99.6% 92.0% 8.0%
Figure 2 Combined results of manual screening, automated screening, and HPV-DNA testing. ASCUS=atypical squamous cells of undetermined signiﬁ-
cance; LSIL=low-grade squamous intraepithelial lesion, HSIL=high-grade squamous intraepithelial lesion; Cancer=invasive squamous cell carcinoma;
HPV=human papillomavirus; HPV+=positive test for HR-HPV types; HPV7=negative test for HR-HPV types.
Table 2 Correlation between AutoPap slide classiﬁcation results and reference cytologic diagnosis
Reference AutoPap slide classiﬁcation results
Cytologic High-score group Low-score group
Diagnoses 1st Rank 2nd Rank 3rd Rank 4th Rank 5th Rank NFR Total
Negative 1116 1273 1323 1328 1362 1922 8324
AGUS 1 1
ASCUS 68 29 15 7 5 3 127
LSIL 84 35 20 19 10 11 179
HSIL 38 4 1 43
Invasive CA 2 2
Total 1308 1341 1360 1354 1377 1936 8676
NFR=no further review; AGUS=atypical glandular cells of underestimated signiﬁcance; ASCUS=atypical squamous cells of
undetermined signiﬁcance; LSIL=low grade squamous intraepithelial lesions; HSIL=high-grade squamous intraepithelial
lesions; invasive CA=invasive squamous cells carcinoma.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 382–388due to screening and/or interpretative errors, mainly due to the
small number of diagnostic cells present in a suboptimal smear
(Vassilakos, 1998b).
Studies carried out elsewhere have also conﬁrmed that the Pap
smear is not a highly effective primary screening test in the
detection of cervical cancer and its precursors (Koss, 1989). It
was found that 40% of cervical cancers occur in women who
recently received negative test results (Slater et al, 1994), and
that a single Pap test misses up to 50% of cervical cancer
precursors (Federal Study, 1999). In England and Wales, 47%
of the invasive cervical cancer found in women under the age
of 70 years occur despite an apparently adequate screening
history (Sasieni et al, 1996).
It has also been demonstrated that false-negative rates of less
than 5% are unlikely to be achieved (Kreiger and Naryshkin,
1994) and may occur even when smears are taken by a gynaecolo-
gist under colposcopy (Beeby et al, 1993). Until a prophylactic
HPV vaccine becomes available, screening will need to be contin-
ued and cervical cytology will necessarily be in a period of
transition. Signiﬁcant improvements are expected with the develop-
ment and wider implementation of new technologies. In
Switzerland, 60% of Pap tests are currently performed with
liquid-based thin-layer technology and are reimbursed by the
health insurance companies (survey of the Swiss Federal Ofﬁce of
Social Insurances). HPV DNA testing, determined from an aliquot
of the same sample used for liquid-based cytology, is also widely
used as a ‘reﬂex’ test to triage patients with ASCUS, thus eliminat-
ing the need for a repeat ofﬁce visit.
It is reasonable to expect that the ultimate way forward in the
next 5–10 years will be the use of standardized liquid-based cyto-
logic preparations, automated screening, HPV DNA testing, early
detection with molecular markers, or completely novel methods.
These technologies can provide improved sensitivity and speciﬁcity
but at increased cost. For this reason, the way in which we use
them will deﬁne the future of cervical cancer prevention. We
believe that they should be considered as complementary diagnostic
tools and not as competing methods. Their combination has been
shown to increase sensitivity and speciﬁcity (Ferenczy et al, 1996;
Vassilakos et al, 1998) and this may allow more cost-effective
screening strategies and improved patient management (Cuzick et
al, 1999; Cuzick and Sasieni, 1999; Solomon et al, 2001).
Our results demonstrate that by using combined technologies a
new strategy can be introduced to screen and manage cervical
cancer precursors (Figure 3).
In common with other studies (Meijer et al, 1998; Cuzick and
Sasieni, 1999), we estimated that approximately 90% of cases are
double-negative screens (HPV-negative/cytology negative). The
potential beneﬁt of this result is that it provides a level of certainty
to women that no signiﬁcant epithelial abnormality has been
missed. Furthermore, savings for the healthcare system may be
achieved by safely lengthening the screening intervals (Cuzick
and Sasieni, 1999). For cases consistently double-negative, screen-
ing may be conducted not only less frequently but even stopped,
especially among older women.
Another positive effect of the proposed diagnostic pathway is the
possibility to reduce laboratory costs related to manual screening.
The latter could be limited to only high-score slides and those
triaged into the low-score/HPV-positive group. Nearly 50% of
slides (low-score/HPV-negative group) could then be archived
without further review since virtually all of them are negative in
the ﬁnal cytologic diagnosis. In 0.4% of these slides, we found
some minor grade abnormalities (eight ASCUS and eight LSIL)
corresponding to a false-negative rate of 5.2%. This rate compares
favourably with the false-negative rate for ASCUS and LSIL
reported in routine practice. The detected abnormalities are
considered to be related to a transient HPV infection or an inﬂam-
mation and will regress spontaneously. It is also highly unlikely
that an underlying HSIL+ lesion will be missed since all HSIL+ will
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CytoRich single specimen
AutoCyte PREP
thin-layer slides
Test for HR-HPV types (Hybrid
Capture II)
AutoPap screener
HPV-DNA testing
Manual screening
Colposcopy Annual
follow-up Colposcopy Colposcopy
Annual
follow-up
Annual
follow-up
3–5 year
follow-up
3–5 year
follow-up
Manual screening Manual screening No review of slides
HPV-DNA testing
High-score Low-score
HPV+ HPV+
HSIL Negative
ASCUS
LSIL
ASCUS+ Negative Negative ASCUS+
2.3% 2.2% 0.0% 1.1% 40.5% 0.4% 4.5% 48.8%
HPV– HPV–
Figure 3 Proposed diagnostic pathway for cervical cancer detection using liquid-based thin-layer slides, computer-assisted screening, and HPV-DNA test-
ing. ASCUS+=atypical squamous cells of undetermined signiﬁcance, low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion,
squamous cell or other carcinoma. HPV=human papillomavirus; HPV+=positive test for HR-HPV types; HPV7=negative test for HR-HPV types.
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British Journal of Cancer (2002) 86(3), 382–388 ã 2002 The Cancer Research Campaignbe triaged into the high-score group. In our study, 95.5% of these
cases were HPV-positive.
The largest volume of patients with abnormal cytology requiring
focused clinical attention and triage concerns those identiﬁed with
ASCUS and LSIL. In the context of an ASCUS cytologic diagnosis,
the triage by HPV DNA testing is considered as a sensitive method
for the detection of an underlying HSIL (Solomon et al, 2001). The
high negative predictive value of the HPV testing may reduce
patient anxiety, prevent overtreatment and potentially save costs
by decreasing repeat visits for equivocal diagnoses. This can be
achieved by adopting a conservative approach for those women
with ASCUS or LSIL who tested negative for HPV.
Based on the results of our study, 2.7% of all screened women
should be referred for immediate colposcopy, 7.8% should return
for a yearly follow-up, and 89.5% could safely lengthen their
screening interval to 3 or even 5 years instead of the yearly interval
currently applied in Switzerland and elsewhere. The colposcopy
referral rate compares favourably with current practice when the
option of direct referral to colposcopy for all ASCUS+ cases is
adopted.
The major advantage of this proposed combined screening
option is the greater protection offered by focusing screening atten-
tion on cases who are at greater risk of having a signiﬁcant cervical
abnormality. In our study population 84.3% of ASCUS+ cases and
100% HSIL+ cases were triaged into the high-score group. Among
these, 57.0% of ASCUS+ and 95.5% of HSIL+ were HPV-positive.
Importantly, one out of two cases assigned to the high-score/HPV-
positive group was reported as ASCUS or worse in the ﬁnal cyto-
logic diagnosis. A quality control rescreening may be applied for
high-score/HPV-positive slides reported as negative by the cyto-
technologists. It can be expected that this measure will enhance
the false-negative detection because it is efﬁciently targeted. It
may be also more cost-effective compared with present practice
since less than 3% of all screened slides will be reviewed instead
of the current 10% random slide selection process. The progressive
rate of HPV positivity related to cervical lesions can also be used as
a quality control of cytopathologic and histopathologic expertise,
particularly concerning excessive cytological diagnoses of minor
cervical abnormalities (ASCUS or LSIL). Failure to detect the
accepted rates would suggest that the Bethesda classiﬁcation criteria
are incorrectly applied.
The ability of this diagnostic pathway to identify cases with a
high probability of abnormality and those that can be archived
without further review will assist cytotechnologists to screen more
accurately slides designated for review. In addition, the tedious part
of manual screening and associated tiredness that occurs when
predominantly normal slides are screened will be signiﬁcantly
reduced since attention is focused to cases at risk.
A problem that may emerge with the introduction of the new
approach is the long-term surveillance of the HPV-positive/
cytology negative cases. We estimate that it will concern approxi-
mately 7% of the screened women in our population. The
clinician caring for the patient may be concerned by the sexual
transmission of the HPV infection or of leaving untreated an
underlying signiﬁcant lesion, and this may lead to an increase in
the number of colposcopies. We consider that the availability of
more accurate information on this topic to women and the clini-
cian would ensure that both would be more at ease with an
annual follow-up only. It should be emphasized that HPV is a very
common virus and for most women the infection is transient and
very unlikely to progress to cancer. Two HPV tests 8 to 12 months
apart are sufﬁcient to allow clearance of infection. Only persistence
of certain types is a risk factor and this risk can be eliminated by
participating in regular recommended cervical screening
programmes. The major concern of our cervical cancer screening
approach is the impact on the cost-effectiveness of this combina-
tion of new technologies. We are presently conducting a study to
evaluate this aspect in detail. Substantial savings are expected to
arise from the extended screening interval, the reduced rate of
recalls, the 50% rate of archived slides requiring no further review
from the cost-effective oriented quality control and from the
reduced screening time of those slides requiring manual review.
Savings in terms of absence from work and travel for unnecessary
repeated tests and treatments, as well as in terms of creating unne-
cessary anxiety to women, need also to be evaluated. The issue of
the age at which to start combined screening tests is another
important component of a successful and cost-effective system
(Cuzick et al, 1999). All the beneﬁts stated above, together with
an increased test sensitivity, could offset the increased cost of the
technology.
In conclusion, our study indicates that a diagnostic pathway
combining new technologies is realistic and has the potential to
improve cervical cancer screening. This approach could be cost-
effective for the patient and clinical practice as it focuses screening
and clinical attention to cases at risk, thus allowing to effectively
test and treat women for signiﬁcant cervical abnormalities. Health-
care costs could be reduced by lengthening screening intervals to
90% of women and by archiving without further review 50% of
the slides. However, additional clinical studies are necessary to vali-
date these preliminary results and to assess the cost-impact of
introducing new technologies.
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